

Torrent Pharma in pact with Reliance Life to sell biosimilars

OUR BUREAU

Ahmedabad, December 25

Ahmedabad-based Torrent Pharmaceuticals Ltd has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars in the Indian market.

In an announcement, Torrent Pharmaceuticals informed that Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent Pharma after obtaining all necessary regulatory approvals.

Torrent Pharma will be the only company to market these biosimilars in India other than Reliance Life Sciences, a company statement said here.

10-year pact

According to the terms of agreement, Reliance Life Sciences will manufacture these products at its facility in Navi Mumbai and supply to Torrent Pharma for 10 years.

Rituximab and Cetuximab cater to the oncology segment and are used in the

Exclusive pact

- Rituximab, Adalimumab and Cetuximab will be developed by Reliance Life Sciences and supplied to Torrent
- Reliance Life Sciences will manufacture these biosimilars at its facility in Navi Mumbai

treatment of various cancers such as leukemia, lymphoma, colorectal, head and neck cancers.

Adalimumab is the most preferred therapy for the treatment of auto immune disorders such as rheumatoid arthritis, psoriasis and IBD.

"Torrent Pharma forayed into the oncology and dermatology segments in 2011-12 with the launch of exclusive divisions and has since gained a strong position in these segments.

"The licensing agreement with Reliance Life Sciences is expected to significantly boost its presence in these segments in the coming years," it said.

Company